Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Insulin detemir is a long-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.
- Mechanism
- Curator reviewed · 9 references
Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.
Insulin detemir’s long duration of action appears to be a result of slow systemic absorption from the injection site and delayed distribution to target tissues. The myristic acid side chain on insulin detemir increases self-association and gives it a high binding affinity to serum albumin. These features slow its distribution into target tissues and prolong its duration of action.
- Primary indication
- Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.Curator reviewed · 5 structured indications
- Formula / weight
- C267H402N64O76S6 · 5916.9 Da
- First approval
- Canada, 2005 · United States, 2006 · European Union, 2016
- Also known as
- Detemir · Insulin detemir recombinant · Insulin,detemir,human
- Code names
- NN-304
- Brand names
- Levemir
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Insulin detemir, and which of those have an active Phase 3 trial?